Auris Story

EARS -- USA Stock

USD 3.28 0.48 17.14%

Macroaxis Story

Whilst many millenniums are getting more into healthcare space, it makes sense to sum up Auris Medical Holding. We are going to cover the possibilities of making Auris Medical into your portfolio. What is Auris Medical valuation so far in 2020? We are going to cover the firm perspective on valuation to give investors a better transparency on taking a position in it.

Published over three months ago

View all stories for Auris Medical | View All Stories

Is Auris Medical Holding outlook positive for October 2020?

This firm currently holds 2.16 M in liabilities with Debt to Equity (D/E) ratio of 39.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. The firm shows a Beta (market volatility) of 0.1474, which signifies not very significant fluctuations relative to the market. Let's try to break down what Auris's beta means in this case. As returns on the market increase, Auris Medical returns are expected to increase less than the market. However, during the bear market, the loss on holding Auris Medical will be expected to be smaller as well. Even though it is essential to pay attention to Auris Medical Holding historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy towards foreseeing any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Auris Medical Holding exposes twenty-eight different technical indicators, which can help you to evaluate its performance. Auris Medical Holding has an expected return of -0.0416%. Please be advised to confirm Auris Medical Holding maximum drawdown, as well as the relationship between the expected short fall and rate of daily change to decide if Auris Medical Holding stock performance from the past will be repeated at some point in the near future.

We determine the current worth of Auris Medical Holding using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Auris Medical Holding based exclusively on its fundamental and basic technical indicators. By analyzing Auris Medical's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Auris Medical's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Auris Medical. We calculate exposure to Auris Medical's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Auris Medical's related companies.

Auris Medical Holding Investment Alerts

Auris investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Auris Medical Holding performance across your portfolios.Please check all investment alerts for Auris

Auris Medical Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Auris value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Auris Medical competition to find correlations between indicators driving the intrinsic value of Auris.

How Auris utilizes its cash?

To perform a cash flow analysis of Auris Medical, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Auris Medical is receiving and how much cash it distributes out in a given period. The Auris Medical cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Auris Medical Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. Auris Medical reported last year Net Cash Flow from Operations of (7.55 Million)

Another Deeper Perspective

Net Loss for the year was (12.5 M) with profit before overhead, payroll, taxes, and interest of 0.

Auris Medical Earnings Before Interest Taxes and Depreciation Amortization EBITDA is relatively stable at the moment. Further, Auris Medical Average Equity is decreasing over the last 7 years. Auris Medical Earnings Before Interest Taxes and Depreciation Amortization EBITDA is decreasing over the last 8 years. The latest value of Auris Medical Earnings Before Interest Taxes and Depreciation Amortization EBITDA is -7,300,467. Further, Auris Medical Average Equity is relatively stable at the moment.

Our perspective of the latest Auris Medical fall

Latest value at risk is at -9.09. As of the 16th of September 2020, Auris Medical shows the mean deviation of 4.6, and Risk Adjusted Performance of (0.028407). Auris Medical Holding technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We are able to interpolate and collect nineteen technical drivers for Auris Medical Holding, which can be compared to its rivals. Please confirm Auris Medical Holding standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and expected short fall to decide if Auris Medical Holding is priced correctly, providing market reflects its regular price of 0.8 per share. Given that Auris Medical is a hitting penny stock territory we recommend to closely look at its total risk alpha.

Our Final Take On Auris Medical

While some firms in the biotechnology industry are either recovering or due for a correction, Auris may not be as strong as the others in terms of longer-term growth potentials. The inconsistency in the assessment between current Auris valuation and our trade advice on Auris Medical is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Auris Medical.

About Contributor

Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management. View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Auris Medical Holding. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2021 Macroaxis LLC